An approach to data collection in compassionate use/managed access
Compassionate Use (CU)/Managed Access programs provide access to locally unapproved medicines. As these programs become more global and involve a broader range of products, determining whether patients derive benefit from treatment could provide insights into therapeutic use in a real-word setting w...
Main Authors: | Séverine Sarp, Ramona Reichenbach, Paul Aliu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1095860/full |
Similar Items
-
Applying real-world data from expanded-access (“compassionate use”) patients to drug development
by: June S. Wasser, et al.
Published: (2023-01-01) -
Outpatient Primary Care Practitioner Access: Gender-Based Preferences
by: Saira J. Khan, et al.
Published: (2022-02-01) -
Taking AIM at serious illness: implementing an access to investigational medicines expanded access program
by: Meghan Morrison Joly, et al.
Published: (2023-10-01) -
Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022
by: Jiayu Wu, et al.
Published: (2023-11-01) -
Perceived compassionate care and associated factors among patients with mental illness at Tibebe Ghion specialized and Felege Hiwot comprehensive specialized hospital, Northwest Ethiopia
by: Agmas Wassie Abate, et al.
Published: (2023-06-01)